US4132738A | 1979-01-02 | |||
US3965143A | 1976-06-22 |
1. | 2 patients with ischaemic peripheral vascular disease. Prostaglandins. 990;39:657664. Ylitalo P, Kauknen S, Reinikainen P, Salenius JP, Vapaatalo H. A randomized, doubleblind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. Int J Clin Pharm Therapy Toxicol. 1 990;28: 1 97204. 1 3 Claims: 1A method of treating arteriosclerosis by chronically augmenting peripheral fibrinolytic function comprising: transderamally administering to a subject in need of such treatment a nonvasodilating fibrinolysis augmenting dosage of a prostaglandin. |
2. | The method of Claim 1 wherein the administration is at least a long term regimen. |
3. | The method of Claim 1 wherein the prostaglandin is selected from the group consisting of PGE1 ( PGE2, PGF2α, PGD2 , or PGI2. |
4. | The method of Claim 3 wherein the prostaglandin is misoprostol. |
5. | The method of Claim 4 wherein the misoprostol is in the { ± )Sform. |
6. | The method of Claim 4 wherein the misoprostol is the ( ± )Rform. |
7. | The method of Claim 4 wherein the dosage is from about 2μg to about 25μg/day. |
8. | The method of Claim 7 wherein the dosage is from about 5μg to about 10μg/day. |
9. | The method of Claim 4 wherein the dosage is from about 05μg/kg/day to about 3.5μg/kg/day. |
10. | 10 The method of Claim 9 wherein the dosage is from about 07μg/kg/day to about 1 .5μg/kg/day. |
11. | 1 . The method of Claim 4 wherein the dosage is at least about 0006μg/hr for said chronically augmenting fibrinolysis. |
12. | 1 2. The method of Claim 4 wherein said dosage is at least about 083μg/liter of blood/day. |
Related Applications
This application claims priority from Provisional Application
60/01 8,828 filed May 30, 1 996.
Background of the Invention
Prostaglandins comprise a class of compounds denominated as
derivatives of the hypothetical prostanoic acid as shown below:
'prostanoic acid'
All naturally occurring prostaglandins have a double bond in the
trans configuration between C-1 3 and C-14; additional double bonds
occur in the cis configuration between C-1 7 and C-18. Prostaglandins are
a collection of short-lived chemical mediators within the body which
control numerous functions, including smooth muscle contraction (as in
peripheral resistance to blood flow through small arteries and degree of
muscular activity in the uterus and small intestines), exocrine gland
secretion (such as tear and saliva flow), and components of the immune
response. The starting material for biosynthesis of these specialized
mediators is a group of substances in the diet called essential fatty acids.
Here, the term "essential" means that the body cannot chemically produce
these starting materials and, like vitamins and certain amino acids, must
1/1
obtain them from the diet. Essential fatty acids are better known by the
term "polyunsaturated fats."
2
Investigational clinical studies of the effect of intravascular infusion
of prostaglandins have been carried out in various subjects, including
some with end-stage arteriosclerotic peripheral vascular disease. Some
studies have found a marked and often persistent clinical improvement in
end-stage arteriosclerotic peripheral vascular disease symptoms. This
effect is noted well beyond the time of prostaglandin infusion for a high
percentage of these patients with end-stage peripheral vascular disease.
The physiologic (or pharmacologic) mechanism by which this clinical
improvement occurs is currently a subject of debate. Furthermore, clinical
application of prostaglandin therapy has been minimal due to the extreme
biochemical instability of the natural prostaglandins and the consequent
difficulty of routinely parenterally administering such unstable compounds.
Attention is drawn to "Prostanoids Stimulate Fibrinolysis in the Rat,"
Arch, int. Pharmacodvn. 296: 155-1 62 (1988); "Effect of Prostacyclin on
Fibrinolytic Activity in Patients with Atherosclerosis Obliterans, "
Dembiήska-Kiec et al., Thromb Haemostas (Stuttgart.. 47(2):1 90 ( 1 982);
"Effect of Prostacyclin (PGI 2 on Platelets and Fibrinolytic Activity in
Patients with Atherosclerosis Obliterans," Dembiήska-Kiec et al.,
Pharmacological Research Communications. 14(6):485-498(1 982); and
"Prostacyclin and the Fibrinolytic System in Ischemic Vascular Disease,"
Szczeklik et al., Thrombosis Research. 29:655-660 (1983), the teachings
of which are incorporated herein by reference.
The E 2 prostaglandin analogue CL1 1 5,347 (Cyanamid International)
has been administered transdermally in a study directed to the treatment
3 of Raynaud's Disease. Blech βt al., "Double-Blind Trial of CL1 1 5,347, a
Transdermally Absorbed Prostaglandin E-, Analogue, in Treatment of
Raynaud's Phenomenon." The Lancet. 1 : 1 180-1 183 (1 985). The authors
particularly note that questions have been raised as to using
prostaglandins at vasodialatory levels or other vasodilator drugs in
atherosclerotic peripheral disease. Id., 1 183. The phenomenon of
generalized vasodilation "stealing" blood from maximally dilated ischemic
areas has been postulated. In clinical practice, stealing is not believed to
be a problem. Vasodilation occurs only at a range of prostaglandin doses
higher than those achieved with clinical intravenous infusion regimens.
Without being bound by any particular theory, it is believed that in the
method of this invention, misoprostol administered as described below
does not substantially dilate ischemic vessels. The data that indicate the
important therapeutic property of prostaglandins in this medical
phenomenon is their property of stimulating endogenous fibrinolysis.
An aspect of this invention is to exploit a route of administration of
the prostaglandin or prostaglandin analog in non-vasodilatory
concentrations which will circumvent the gastrointestinal effects of oral
prostaglandin administration. This aspect is particularly distinct from the
presentation with regard to vasospastic disease (i.e. in Raynaud's
disease). Atherosclerotic disease has a distinct etiology from other
vascular disease. The present invention addresses delivery by the patch of
a stimulator of endogenous fibrinolytic activity.
4 In one embodiment, the practice of this invention is particularly
directed to transdermal delivery of an endogenous stimulator of fibrinolytic
activity, such as prostaglandins, and, more particularly, at non-
vasodilatory levels.
Chemical modifications have been made to the various
prostaglandins so as to allow a pharmacologically effective dose to be
given by oral administration. Orally administered prostaglandin analogs
have a very pronounced pharmacologic effect on the motility of the
gastrointestinal musculature (due to the high concentration of the drug in
the GI tract) resulting in a dose-dependent side effect of diarrhea. This
side effect markedly limits the dose that can be administered such that
the resulting dose entering the blood stream tends to be very small.
In 1 973, Carlson and Eriksson ( 1 ) conducted a study of the effect
of intra-arterial infusion of prostaglandin E, on the symptoms and outcome
of end-stage peripheral vascular disease. In this study, the term 'end-
stage' was defined as a clinical condition of existing or impending
extremity gangrene due to ischemia and/or extreme continuous pain at
rest. The study reports that all subjects noted pain at rest either to
disappear promptly or to improve markedly. Gangrene present in two of
the patients markedly improved. None of the patients required amputation
of the involved limb during the study period even though, during the prior
interval of conventional therapy, all had deteriorated to the point where
amputation was considered imminent. Subsequent studies (2-1 2) have
replicated these results and have shown that the beneficial effect can
5 occur with intravenous as well as intra-arterial infusion. Also of note is
the finding that substantial benefit can persist for more than four months
after the infusion period. Despite the significant clinical improvement that
occurs with the infusion of several prostaglandins (PGE,, PGI 2
(prostacyclin), and iloprost (a prostacyclin analog)), this finding remains a
clinical curiosity. Hitherto, it has not been feasible to incorporate long
term prostaglandin administration into routine medical practice due to the
unstable nature of these compounds and the complexities of the infusion
procedure.
Chemical analogs of several of the native prostaglandins have been
developed to circumvent problems of clinical administration, but have
been unsuccessful. These analogs possess biological activity similar to
the native compound, but are biologically degraded much more slowly (on
the order of tens of minutes versus a few seconds ). Some are also
reasonably stable at the level of acidity found in the stomach and can thus
be effective if given orally. An example of this kind of chemical analog is
misoprostol, ( 1 1 ,1 3E)-( ±)-1 1 , 1 6-Dihydroxy-1 6-methyl-9-oxoprost-1 3-en-
1 -oic acid methyl ester, a compound with the biological activity of
prostaglandin E, (Cytotec ® , G. D. Searle). Other suitable prostaglandins
are those of the E, and E 2 series, as well as PGF 2α (semistable), PGD 2 ,
PGI 2 (prostacyclin). It is understood that analogues and derivatives of
these compounds with similar fibrinolytic bioactivity are also
contemplated.
6 Misoprostol is described in the literature as a prescription
medication which stimulates the production of mucous and bicarbonate
ions by the stomach and intestinal lining, thus protecting these areas from
gastric acid damage. Misoprostol mimics these effects and is helpful in
healing ulcers. However, both PGE, and misoprostol also increase
intestinal muscular activity and thus cause dose-dependent diarrhea,
which markedly limits the dose that can be given by mouth. As a result,
the amount of misoprostol that is absorbed into the blood steam is
reduced to the extent that the drug given orally cannot effectively
reproduce the benefits of i.v. infusion of PGE, .
To achieve a reasonable level of medication in the bloodstream,
without an unacceptable degree of gastrointestinal stimulation, an
alternative route of administration is required. This alternative method
must also avoid the complexities of direct intravascular infusion
procedures.
Transdermal drug administration is known in the pharmaceutical art.
Examples of transdermal drug administration include clonidine
administration in hypertension (Catapres Transdermal Therapeutic System,
Boehinger Ingelhiem), estridiol administration in estrogen replacement
therapy (Estraderm Transdermal System, Ciba Pharmaceutical),
nitroglycerin administration for the treatment of coronary artery disease
(Nitro-Dur, Key Pharmaceuticals), nicotine administration for smoking
cessation (Habitrol Nicotine Transdermal, Basel; Nicoderm Nicotine
Transdermal System, Marion Merrell Dow), scopolamine administration for
7 motion sickness (Transderm Scop Transdermal Therapeutic System, Ciba
Consumer), and fentanyl administration for pain control (Duragesic
Transdermal System, Janssen Pharmaceutica.
Summary of the Invention
Administration of either native prostaglandins or prostaglandin
analogs by an extended release dermal patch circumvents problems
associated with other routes of prostaglandin administration. This method
allows much higher levels of medication to be absorbed into the skin and,
subsequently, directly into the parenteral circulation without undesirable
gastrointestinal side effects.
This invention comprises a method of treating arteriosclerosis by
chronically augmenting peripheral fibrinolytic function comprising:
transdermally administering to a subject in need of such treatment a
non-vasodilating fibrinolysis augmenting dosage of a prostaglandin.
Particular note is made of the use of administration by at least a long term
regimen. In particular cases, administration of a non-vasodilating
fibrinolysis augmenting dosage of a prostaglandin every day, or every
other day for a period of at least about 1 2 months are contemplated. In
specific applications where peripheral ulcers are a presenting clinical
problem, treatment may be extended until healing of the ulcers.
In some embodiments of the invention the prostaglandin is selected from the group consisting of misoprostol, prostacyclin, E, and E 2 series
8 prostaglandins, as well as PGF 2α and PGD 2< Particular note is made of
the prostaglandin misoprostol, and further of misoprostol in the ( ± )-S-
form and in the ( ± )-R-form.
In some embodiments, misoprostol is administered from about 2μg
to about 25μg/day, and particularly from about 5μg to about 10μg/day.
Also noted is the administration of misoprostol from about 0.5μg/kg/day
to about 3.5μg/kg/day, and also from about 0.7μg/kg/day to about
1 .5μg/kg/day. Specifically contemplated is the method of this invention
wherein the misoprostol dosage is at least about 0.006μg/hr as well as at
least about 0.83μg/liter of blood/day.
In the broad embodiments, the method includes a dosage of
prostaglandin from about 2μg to about 25μg/day, and particularly from
about 5μg to about 10μg/day. Also contemplated is a dosage from about
0.5μg/kg/day to about 3.5μg/kg/day.
Also contemplated in the method is infusion of prostaglandin and
especially misoprostol at a rate of about 1 to about 6ng/hr, and
particularly from about 2 to about 5 ng/hr.
A particular embodiment of this invention includes a method of
treating arteriosclerosis by chronically augmenting peripheral fibrinolytic
function comprising administration to a subject in need of such treatment
a non-vasodilating fibrinolysis augmenting dosage of a prostaglandin by
buccal or sublingual administration, or by nasal administration (such as by
spray or by inhalation such as via a nebulizer generated prostaglandin
containing mist).
Detailed Description of the Invention
This invention is best understood with resort to the following
definitions:
A and B. "Chronically" maintaining as non-vasodilating peripheral levels
of augmented fibrinolysis over at least about 1 0 hours. In contrast, the
term "long term regimen" shall refer to repeated chronic daily maintaining
of drug levels over periods of at least about 1 5 days in a 60 day period.
C. "Peripheral," as to augmented fibrinolysis, shall mean limbs, including
digits, ears, and nose.
D. "Augmented, " as to fibrinolytic activity, shall mean at least a 30%
increase over the non-treated state for a given subject averaged over the
time of daily administration.
E. "Non-vasodilating" shall mean not greater that 20% increase in blood
flow increase averaged over the time of daily administration
F. "Transdermal" is used to encompass patch-type delivery. While
buccal, intranasal, inhalation and other delivery of drugs are also
contemplated, the use of such routes will be specifically addressed when
these routes are intended.
G. "Subjects" is used expansively to include animals, mammals and,
particularly, humans.
The present invention enables sustained effective levels of a
prostaglandin or a prostaglandin analog to be absorbed into the blood
while avoiding undesirable gastrointestinal adverse effects by way of a
10 dermally applied patch. This invention specifically addresses the use of
prostaglandins or their analogs for the therapy of arteriosclerosis including
microvascular disease often seen in diabetes mellitus.
While particular doses are set forth, it is specifically to be
understood that specific subjects and specific prostaglandins will present
unique sensitivity to prostaglandin therapy. A non-vasodilating dose can
be determined by administering increasing or decreasing doses of a
particular prostaglandin to a subject to determine when vasodilation is
encountered. A skilled practitioner in the art will appreciate that ambient
temperature will have an effect on testing and should be accounted for.
However, a peripheral color change or temperature increase or pulse
amplitude discloses vasodilation.
Similarly, increased fibrinolytic activity may be easily determined by
any of a number of tests for fibrinolysis/fibrinolytic activity. Several tests
of fibrinolytic are presented in "Fibrinolysis induced by Streptokinase in
Man," Nilsson et al., Acta Chir Scand. 1 23:247-266 ( 1 962) the teachings
of which are incorporated herein by reference.
Articles of interest include:
Carlson LA, Eriksson I. Femoral-artery infusion of prostaglandin E,
in severe peripheral vascular disease. Lancet. 1973; 1 :1 55-1 56.
Carlson LA, Olsson AG. Intravenous prostaglandin E, in severe
peripheral vascular disease. Lancet. 1 976;2:810.
Sakaguchi S, Kusaba A, Mishima Y, Kamiya K, Nishimura A,
Furukawa K, Shionoya S, Kawashima M, Katsumura T, Sakuma A. A
1 1 multi-clinical double blind study with PGE, { -cyclodextrin clathrate) in
patients with ischemic ulcer of the extremities. Vasa. 1 978;7:263-266.
Szczeklik A, Nizankowski R, Skawinski S, Szczeklik J, Gluszko P,
Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans
with prostacyclin. Lancet. 1979;1 : 1 1 1 1 -1 1 14.
Olsson AG. Intravenous prostacyclin for ischemic ulcers in
peripheral artery disease. Lancet. 1980;2:1076.
Sethi GK, Scott SM, Takaro T. Effect of intra-arterial infusion of
PGE, in patients with severe ischemia of lower extremity. J Cardiovas.
Sure. 1 980;21 : 1 85-192.
Pardy BJ, Lewis JD, Eastcott HHG. Preliminary experience with
prostaglandins E, and l 2 in peripheral vascular disease. Surgery.
1 980;88:826-832.
Kyle V, Hazleman B. Prostaglandin E, and peripheral vascular
disease. Lancet. 1 983;2:282.
Siegel RJ, Shah PK, Nathan M, Rodriguez L, Shell, WE.
Prostaglandin E, infusion in unstable angina: effects on anginal frequency
and cardiac function. Am Heart J. 1 984; 108:863-868.
Balzer K, Rogatti W, Ruttgerodt K. Efficacy and tolerability of intra-
arterial and intravenous prostaglandin E, infusions in occlusive arterial
disease stage lll/IV. Vasa Suppl. 1989;28:31 -38.
Virgolini I, Fitscha P, Linet Ol, O'Grady J, Sinzinger H. A double
blind placebo controlled trial of intravenous prostacyclin (PGI 2 ) in 108